Fenwick represented Freenome, a privately held biotech company, in its $290 million investment from Roche Diagnostics. The investment brings Freenome’s total funding to more than $1.1 billion since the company’s founding in 2014.
Roche’s investment will allow Freenome to further accelerate and augment the development of its multiomics platform for early cancer detection to test for additional cancers and expand its real-world data programs. More information can be obtained from Freenome’s announcement.
The Fenwick transaction team included corporate partners Michael Esquivel and Patrick Grilli and associates Caroline Wells, R. Harrison Dilday and Brandon Ho; and life sciences partner Stefano Quintini.